This study is looking at how well and how safely Mirikizumab works for adults aged 60 and older who have moderate to severe Crohn's disease (CD) or ulcerative colitis (UC). These are types of inflammatory bowel disease (IBD) that cause swelling and irritation in your digestive system. Mirikizumab is already approved for IBD, but there's not much information about its use in older adults, who often have other health concerns. This study aims to see if Mirikizumab can help older patients manage their condition safely. Success will be measured by whether participants achieve clinical remission (a significant reduction in symptoms) at 24 weeks.

Study design

This is an interventional study planning to enroll about 150 participants. It will test Mirikizumab according to FDA-approved dosing guidelines, without a comparison group.

What's involved

Participants will receive scheduled doses of Mirikizumab at predefined intervals throughout the study period. Clinical remission will be measured at 24 weeks.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint for measuring clinical remission is at 24 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.